Pluristem Therapeutics

company

About

Pluristem Therapeutics is a biotherapy company using placental cells and a 3D technology platform to develop cell therapies for diseases.

  • 101 - 250

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€50M
Industries
3D Technology,Biotechnology,Therapeutics
Founded date
Jan 1, 2003
Number Of Employee
101 - 250
Operating Status
Active

Pluristem Therapeutics is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. These cells are converted into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. Pluristem’s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells require no tissue matching prior to administration, making them an “off-the-shelf” product. The company’s GMP-certified in-house manufacturing facilities allow it to efficiently produce commercial quantities of homogeneous, clinical-grade PLX cells. Pluristem is currently the only company manufacturing large quantities of placenta-based cell products using a 3D bioreactor. Driving these development efforts is a management team dedicated to shaping the future of the company and of placenta-based cell therapies. The Pluristem team has many decades of industry and research experience and draws on this as it continues to progress towards company goals.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€50M
Pluristem Therapeutics has raised a total of €50M in funding over 2 rounds. Their latest funding was raised on Apr 24, 2020 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 24, 2020 Post-IPO Debt €50M 1 European Investment Bank Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Pluristem Therapeutics is funded by 1 investors. European Investment Bank are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Post-IPO Debt